Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

Completed · Phase 4 · Has a placebo group

Conditions studied: Insulin Resistance, Type 2 Diabetes Mellitus

In brief

The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.

Key facts

Study ID

NCT00212290

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

People needed

140

Starts

2002-11-01

Expected to finish

2006-12-01

Last updated by the study team

2010-02-15

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Impaired glucose tolerance OR mild type 2 diabetes mellitus OR normal blood sugar regulation
• Stable weight and activity level

You may not qualify if…

• Medications for diabetes
• Dementia
• Medications with known effects on memory
• Serious neurologic disease or head trauma
• Serious systemic illness (e.g., renal failure or uncontrolled hypertension)
• Serious psychiatric illness (e.g., schizophrenia or bipolar disorder)
• Allergy to pioglitazone or nateglinide

Where it is running

• VA Puget Sound Health Care System (Seattle Campus) — Seattle, Washington, United States
• VA Puget Sound Health Care System (American Lake Campus) — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.